title: Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
abstract: We compared the diagnostic value of [18F]2-fluoro-2-deoxy-D-glucose (FDG) PET imaging and 201Tl SPECT imaging in the detection of primary lung cancer and mediastinal lymph node metastases.
  
  
  METHODS
  Thirty-three patients with histologically-proven primary lung cancer were examined with both FDG PET and TI SPECT (early and delayed scans) within a week of each study. For semiquantitative analysis, the tumor-to-nontumor activity ratio (T-to-N ratio) was calculated.
  
  
  RESULTS
  Although both techniques delineated focal lesions with an increase in tracer accumulation in 28 patients, PET identified three additional patients in whom Tl SPECT images did not visualize any lesions on both early and delayed scans. In the detection of lung cancer of less than 2 cm in size, FDG PET provided higher sensitivity (six of seven, 85.7%) than did Tl SPECT early scan (one of seven, 14.3%) and delayed scan (four of seven, 57.1%). Neither technique visualized any lesions in two patients who had bronchioloalveolar carcinoma. The T-to-N ratio was significantly higher with FDG PET (10.39 +/- 6.63) than it was with Tl SPECT (early scan, 2.37 +/- 0.86; delayed scan, 3.01 +/- 1.01) (p < 0.0001), whereas there was significant positive correlation between the FDG T-to-N ratio and the thallium T-to-N ratio (p < 0.01). Twenty-two patients had thoracotomies. Regarding the staging of mediastinal nodes, FDG PET detected mediastinal lymph node metastasis that was negative on Tl SPECT, whereas both techniques excluded tumor involvement in enlarged node at CT.
  
  
  CONCLUSIONS
  Both techniques have clinical value for the noninvasive detection of primary lung cancer that is 2 cm or greater in diameter. However, if a PET camera is available, FDG PET is considered the method of choice for the evaluation of patients with suspected primary lung cancer that is less than 2 cm in diameter.
authors.affiliation: Department of Radiology, Kanazawa Medical University, Ishikawa, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Higashi
authors.forename: T
authors.initials: T
authors.lastname: Nishikawa
authors.forename: H
authors.initials: H
authors.lastname: Seki
authors.forename: M
authors.initials: M
authors.lastname: Oguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Nambu
authors.forename: Y
authors.initials: Y
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Yuasa
authors.forename: H
authors.initials: H
authors.lastname: Tonami
authors.forename: T
authors.initials: T
authors.lastname: Okimura
authors.forename: I
authors.initials: I
authors.lastname: Yamamoto
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis; D008297:Male; D008482:Mediastinum; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013794:Thallium Radioisotopes; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D013794:Thallium Radioisotopes; D019788:Fluorodeoxyglucose F18